GeneReach Biotechnology Corp. (TPEX:4171)
Taiwan · Delayed Price · Currency is TWD 21.50
+0.05 (0.23%)
Jan 22, 2026, 11:59 AM CST
GeneReach Biotechnology Revenue
GeneReach Biotechnology had revenue of 53.39M TWD in the quarter ending September 30, 2025, a decrease of -14.52%. This brings the company's revenue in the last twelve months to 215.32M, up 4.35% year-over-year. In the year 2024, GeneReach Biotechnology had annual revenue of 206.49M, down -8.41%.
Revenue (ttm)
215.32M
Revenue Growth
+4.35%
P/S Ratio
5.76
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.24B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 206.49M | -18.97M | -8.41% |
| Dec 31, 2023 | 225.46M | -524.56M | -69.94% |
| Dec 31, 2022 | 750.02M | -262.06M | -25.89% |
| Dec 31, 2021 | 1.01B | 155.04M | 18.09% |
| Dec 31, 2020 | 857.03M | 491.24M | 134.29% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Level Biotechnology | 753.30M |
| Meribank Biotech | 486.52M |
| Taiwan Advance Bio-Pharmaceutical | 371.86M |
| Abnova (Taiwan) | 355.40M |
| TCI GENE | 324.73M |
| Lukas Biomedical | 180.32M |
| NatureWise Biotech & Medicals | 180.29M |
| Holy Stone Healthcare | 47.51M |